JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Intuitive Surgical (NASDAQ:ISRG) Stock

Intuitive Surgical (NASDAQ:ISRG) had its price objective lifted by equities research analysts at JPMorgan Chase & Co. from $450.00 to $475.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 10.59% from the stock’s current price.

A number of other research analysts also recently commented on the company. Piper Sandler reissued an “overweight” rating on shares of Intuitive Surgical in a report on Friday, August 21st. HSBC lowered Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price objective for the company. in a research note on Thursday, July 30th. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. Robert W. Baird upped their target price on Intuitive Surgical from $513.00 to $550.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Intuitive Surgical in a research note on Monday, July 20th. Twenty-five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $498.31.

Intuitive Surgical Trading Down 1.9%

ISRG stock traded down $8.47 during trading on Wednesday, reaching $429.53. The stock had a trading volume of 2,088,937 shares, compared to its average volume of 2,412,223. The firm has a fifty day moving average price of $392.96 and a 200 day moving average price of $409.06. The company has a market capitalization of $151.74 billion, a P/E ratio of 48.97, a PEG ratio of 3.27 and a beta of 1.46. Intuitive Surgical has a 1-year low of $328.57 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. During the same period last year, the firm earned $2.40 earnings per share. The company’s revenue was up 21.7% on a year-over-year basis. Sell-side analysts predict that Intuitive Surgical will post 8.87 EPS for the current year.

Insider Buying and Selling

In related news, EVP Mark Brosius sold 77 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the sale, the executive vice president directly owned 881 shares of the company’s stock, valued at approximately $330,877.17. This represents a 8.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the transaction, the executive vice president owned 5,320 shares in the company, valued at $2,016,280. This trade represents a 6.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 12,370 shares of company stock worth $4,891,989. 0.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in Intuitive Surgical in the second quarter valued at approximately $1,335,753,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Intuitive Surgical by 55.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,557,940 shares of the medical equipment provider’s stock valued at $633,505,000 after purchasing an additional 558,099 shares during the last quarter. Amundi raised its position in shares of Intuitive Surgical by 8.6% during the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after purchasing an additional 193,096 shares during the period. Finally, Temasek Holdings Private Ltd raised its position in shares of Intuitive Surgical by 416.4% during the 1st quarter. Temasek Holdings Private Ltd now owns 227,211 shares of the medical equipment provider’s stock worth $104,742,000 after purchasing an additional 183,211 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Underlying operating results were strong: revenue increased 21.7% year over year to $3.05 billion, while adjusted earnings reached $3.00 per share versus consensus estimates near $2.61–$2.65. Worldwide procedures grew approximately 15%, and da Vinci system placements rose to 546 from 427 a year earlier. Intuitive Surgical’s Q3 Earnings Beat Estimates on Strong System Sales
• Positive Sentiment: Analyst support remains broadly favorable. Bernstein reaffirmed a Buy rating with a $685 target, BTIG maintained Buy, Baird raised its target to $550, and Erste Group upgraded the stock from Hold to Buy. ISRG also crossed above its 200-day moving average, a technical signal that can indicate improving long-term momentum. Bernstein Reaffirms Buy Rating
• Neutral Sentiment: Analyst revisions were mixed after the report. RBC lowered its target to $550 but kept Outperform, Raymond James trimmed its target to $480, and Mizuho cut its target to $400 with a Neutral rating. RBC Capital Adjusts Price Target
• Negative Sentiment: A $450 million pretax charge tied to a proposed antitrust settlement reduced GAAP earnings to $1.49 per share from $1.95 a year earlier. The settlement remains subject to court approval, adding legal and financial uncertainty. Intuitive Surgical Stock Slides Despite Earnings Beat
• Negative Sentiment: Management narrowed its 2026 da Vinci procedure-growth forecast to 14%–15% and plans pricing actions that could reduce revenue per procedure by 3%–5%. Reports also highlighted a U.S. procedure slowdown, increasing concern that growth may moderate despite continued system demand. Intuitive Narrows 2026 Procedure Growth Outlook

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.